📊 ROIV Key Takeaways
Is Roivant Sciences Ltd. (ROIV) a Good Investment?
Roivant Sciences is a pre-revenue stage pharmaceutical company with minimal revenue ($5.7M) and massive operating losses (-$930.3M), burning cash at an unsustainable rate of -$593.5M annually in free cash flow. While the company maintains a strong balance sheet with $1.5B in cash and low debt (0.07x D/E), this provides only ~2.5 years of runway at current burn rates with no visible path to profitability or commercial viability.
Fundamentals show minimal revenue with extremely large operating and free cash flow losses, indicating no path to near-term profitability. While liquidity is exceptionally strong and leverage is low, negative revenue growth and inability to cover interest from operations make the risk/reward unattractive on fundamentals alone.
Why Buy Roivant Sciences Ltd. Stock? ROIV Key Strengths
- Strong liquidity position with $1.5B in cash and 30.66x current ratio
- Conservative capital structure with minimal debt (Debt/Equity 0.07x) and low financial risk
- Solid equity base of $4.3B providing balance sheet cushion for continued operations
- Exceptional liquidity (current/quick >30x) and $1.48B cash
- Low leverage (0.07x D/E) with substantial equity base
- Capex-light model and YoY improvement in net loss
ROIV Stock Risks: Roivant Sciences Ltd. Investment Risks
- Unsustainable cash burn of -$593.5M annually will deplete cash reserves within 2-3 years without material revenue growth
- Revenue base of only $5.7M with -11.2% YoY decline indicates failed commercialization efforts or non-viable product portfolio
- Massive operating losses (-$930.3M) and negative operating margin of -16,207.5% demonstrate fundamental operational failure to generate revenue from cost structure
- No evidence of near-term catalysts for profitability or successful drug development in provided data
- Sustained large operating losses and deeply negative FCF
- Tiny, declining revenue base with poor operating leverage
- Negative interest coverage and elevated dilution/financing risk
Key Metrics to Watch
- Revenue growth rate and pipeline advancement toward FDA approvals
- Quarterly cash burn rate and months of cash runway remaining
- Operating expense reduction initiatives and path to operating break-even
- Quarterly operating cash burn vs cash runway
- Revenue growth from partnerships/licensing
Roivant Sciences Ltd. (ROIV) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 30.66x current ratio provides a solid financial cushion.
ROIV Profit Margin, ROE & Profitability Analysis
ROIV vs Healthcare Sector: How Roivant Sciences Ltd. Compares
How Roivant Sciences Ltd. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Roivant Sciences Ltd. Stock Overvalued? ROIV Valuation Analysis 2026
Based on fundamental analysis, Roivant Sciences Ltd. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Roivant Sciences Ltd. Balance Sheet: ROIV Debt, Cash & Liquidity
ROIV Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Roivant Sciences Ltd.'s revenue has declined by 41% over the 5-year period, indicating business contraction. The most recent EPS of $-1.42 indicates the company is currently unprofitable.
ROIV Revenue Growth, EPS Growth & YoY Performance
ROIV Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.0M | $34.5M | $0.05 |
| Q2 2025 | $1.6M | -$113.5M | $-0.17 |
| Q1 2025 | $2.2M | $95.3M | $0.12 |
| Q3 2024 | $9.0M | $34.5M | $0.05 |
| Q2 2024 | $3.6M | -$134.9M | $-0.18 |
| Q1 2024 | $21.6M | $95.3M | $0.12 |
| Q3 2023 | $17.1M | -$352.0M | $-0.49 |
| Q2 2023 | $12.5M | -$291.6M | $-0.40 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Roivant Sciences Ltd. Dividends, Buybacks & Capital Allocation
ROIV SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Roivant Sciences Ltd. (CIK: 0001635088)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ROIV
What is the AI rating for ROIV?
Roivant Sciences Ltd. (ROIV) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 81% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ROIV's key strengths?
Claude: Strong liquidity position with $1.5B in cash and 30.66x current ratio. Conservative capital structure with minimal debt (Debt/Equity 0.07x) and low financial risk. ChatGPT: Exceptional liquidity (current/quick >30x) and $1.48B cash. Low leverage (0.07x D/E) with substantial equity base.
What are the risks of investing in ROIV?
Claude: Unsustainable cash burn of -$593.5M annually will deplete cash reserves within 2-3 years without material revenue growth. Revenue base of only $5.7M with -11.2% YoY decline indicates failed commercialization efforts or non-viable product portfolio. ChatGPT: Sustained large operating losses and deeply negative FCF. Tiny, declining revenue base with poor operating leverage.
What is ROIV's revenue and growth?
Roivant Sciences Ltd. reported revenue of $5.7M.
Does ROIV pay dividends?
Roivant Sciences Ltd. does not currently pay dividends.
Where can I find ROIV SEC filings?
Official SEC filings for Roivant Sciences Ltd. (CIK: 0001635088) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ROIV's EPS?
Roivant Sciences Ltd. has a diluted EPS of $-0.88.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ROIV a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Roivant Sciences Ltd. has a SELL rating with 81% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ROIV stock overvalued or undervalued?
Valuation metrics for ROIV: ROE of -14.1% (sector avg: 15%), net margin of -10,501.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ROIV stock in 2026?
Our dual AI analysis gives Roivant Sciences Ltd. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ROIV's free cash flow?
Roivant Sciences Ltd.'s operating cash flow is $-586.5M, with capital expenditures of $6.9M. FCF margin is -10,339.4%.
How does ROIV compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -10,501.1% (avg: 12%), ROE -14.1% (avg: 15%), current ratio 30.66 (avg: 2).